Drug reference
iron-sorbitol-citric acid
Parenteral iron preparation · Haematinic
Parenteral iron preparationHaematinicATC B03AC
CDSCO approvedATC B03AC
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
C
FDA category + note
Mechanism
A low molecular weight complex absorbed directly into circulation, binding to transferrin in plasma.
Indications
When oral iron is not toleratedFailure to absorb oral iron (malabsorption, inflammatory bowel disease, chronic inflammation)Non-compliance to oral ironSevere deficiency with chronic bleedingAlong with erythropoietin (to meet demands of induced rapid erythropoiesis)
Dosing
- Adult
- 75 mg i.m. (max 100 mg) daily or on alternate days. The calculated total dose has to be increased due to urinary excretion.
Pharmacokinetics
Excretion
about 30% of the dose is excreted in urine
Contraindications
- i.v. injection or infusion
- patients with kidney disease
Side effects
Common
urine turns brownimmediate reaction, including ventricular tachycardiaA-V blockother irregularitieshypotensionflushing
Serious
- remaining free iron is highly toxic (if given i.v.)
Pregnancy & lactation
Pregnancy
C
Related guidelines
Other Parenteral iron preparation drugs
Ask House about iron-sorbitol-citric acid
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e·Verified: 2026-05-10 · House clinical team